KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novavax (NVAX) Accumulated Expenses: 2009-2025

Historic Accumulated Expenses for Novavax (NVAX) over the last 16 years, with Sep 2025 value amounting to $115.6 million.

  • Novavax's Accumulated Expenses fell 47.14% to $115.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $115.6 million, marking a year-over-year decrease of 47.14%. This contributed to the annual value of $211.2 million for FY2024, which is 46.50% down from last year.
  • Novavax's Accumulated Expenses amounted to $115.6 million in Q3 2025, which was up 33.32% from $86.7 million recorded in Q2 2025.
  • Novavax's 5-year Accumulated Expenses high stood at $673.7 million for Q4 2021, and its period low was $86.7 million during Q2 2025.
  • Moreover, its 3-year median value for Accumulated Expenses was $218.7 million (2024), whereas its average is $260.3 million.
  • Its Accumulated Expenses has fluctuated over the past 5 years, first soared by 1,385.52% in 2021, then slumped by 65.27% in 2024.
  • Novavax's Accumulated Expenses (Quarterly) stood at $673.7 million in 2021, then decreased by 12.26% to $591.2 million in 2022, then slumped by 33.24% to $394.7 million in 2023, then crashed by 46.50% to $211.2 million in 2024, then slumped by 47.14% to $115.6 million in 2025.
  • Its Accumulated Expenses was $115.6 million in Q3 2025, compared to $86.7 million in Q2 2025 and $132.2 million in Q1 2025.